Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.75 AUD | 0.00% | -1.69% | -9.09% |
19/03 | Cyclopharm's Technegas Device Carries Out Imaging of First US Patients | MT |
18/03 | Cyclopharm Limited(ASX:CYC) added to S&P/ASX All Ordinaries Index | CI |
Sales 2024 * | 37.4M 24.43M 2.04B | Sales 2025 * | 60.9M 39.78M 3.32B | Capitalization | 165M 108M 8.98B |
---|---|---|---|---|---|
Net income 2024 * | -2M -1.31M -109M | Net income 2025 * | 11M 7.19M 599M | EV / Sales 2024 * | 4.41 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.71 x |
P/E ratio 2024 * |
-69.7
x | P/E ratio 2025 * |
14.3
x | Employees | 87 |
Yield 2024 * |
0.57% | Yield 2025 * |
3.5% | Free-Float | 45.15% |
1 week | -1.69% | ||
Current month | -2.51% | ||
1 month | -2.78% | ||
3 months | -5.41% | ||
6 months | -18.98% | ||
Current year | -9.09% |
Managers | Title | Age | Since |
---|---|---|---|
James McBrayer
CEO | Chief Executive Officer | 58 | 03/08/03 |
Mathew Farag
COO | Chief Operating Officer | - | 01/17/01 |
Mark Doverty
PRN | Corporate Officer/Principal | - | 30/19/30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dianne Angus
BRD | Director/Board Member | 63 | 10/21/10 |
James McBrayer
CEO | Chief Executive Officer | 58 | 03/08/03 |
David Heaney
CHM | Chairman | 79 | 20/06/20 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 1.75 | 0.00% | 220 |
24/24/24 | 1.75 | -1.69% | 18,513 |
22/24/22 | 1.78 | 0.00% | 12,000 |
19/24/19 | 1.78 | 0.00% | 14,941 |
18/24/18 | 1.78 | -1.11% | 15,980 |
Delayed Quote Australian S.E., April 26, 2024 at 05:32 am IST
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-9.09% | 107M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- CYC Stock